Best of AACR Journals

More documents

Recommendations

Info

Molecular Cancer Therapeutics Research Article NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants Nagalakshmi Nadiminty, Ramakumar Tummala, Chengfei Liu, Joy Yang, Wei Lou, Christopher P. Evans, and Allen C. Gao Nagalakshmi Nadiminty Allen C. Gao Abstract Resistance of prostate cancer cells to the next-generation antiandrogen enzalutamide may be mediated by a multitude of survival signaling pathways. In this study, we tested whether increased expression of NF-κB2/p52 induces prostate cancer cell resistance to enzalutamide and whether this response is mediated by aberrant androgen receptor (AR) activation and AR splice variant production. LNCaP cells stably expressing NF-κB2/p52 exhibited higher survival rates than controls when treated with enzalutamide. C4-2B and CWR22Rv1 cells chronically treated with enzalutamide were found to express higher levels of NF-κB2/p52. Downregulation of NF-κB2/p52 in CWR22Rv1 cells chronically treated with enzalutamide rendered them more sensitive to cell growth inhibition by enzalutamide. Analysis of the expression levels of AR splice variants by quantitative reverse transcription PCR and Western blotting revealed that LNCaP cells expressing p52 exhibit higher expression of AR splice variants. Downregulation of expression of NF-κB2/p52 in VCaP and CWR22Rv1 cells by short hairpin RNA abolished expression of splice variants. Downregulation of expression of either full-length AR or the splice variant AR- V7 led to an increase in sensitivity of prostate cancer cells to enzalutamide. These results collectively demonstrate that resistance to enzalutamide may be mediated by NF-κB2/p52 via activation of AR and its splice variants. Mol Cancer Ther; 12(8); 1629–37. ©2013 AACR. Mol Cancer Ther August 2013 12:1629–37; Published OnlineFirst May 22, 2013; doi:10.1158/1535-7163.MCT-13-0027 Research Article Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death Grazia Ambrosini, Elgilda Musi, Alan L. Ho, Elisa de Stanchina, and Gary K. Schwartz Abstract Grazia Ambrosini Oncogenic mutations in GNAQ and GNA11 genes are found in 80% of uveal melanoma. These mutations result in the activation of the RAF/MEK signaling pathway culminating in the stimulation of ERK1/2 mitogen-activated protein kinases. In this study, using a siRNA strategy, we show that mutant GNAQ signals to both MEK and AKT, and that combined inhibition of these pathways with the MEK inhibitor selumetinib (AZD6244) and the AKT inhibitor MK2206 induced a synergistic decrease in cell viability. This effect was genotype dependent as autophagic markers like beclin1 and LC3 were induced in GNAQ-mutant cells, whereas apoptosis was the mechanism of cell death of BRAF-mutant cells, and cells without either mutation underwent cell-cycle arrest. The inhibition of MEK/ATK pathways induced activation of AMPactivated protein kinase (AMPK) in the GNAQ-mutant cells. The downregulation of AMPK by siRNA or its inhibition with compound C did not rescue the cells from autophagy, rather they died by apoptosis, defining AMPK as a key regulator of mutant GNAQ signaling and a switch between autophagy and apoptosis. Furthermore, this combination treatment was effective in inhibiting tumor growth in xenograft mouse models. These findings suggest that inhibition of MEK and AKT may represent a promising approach for targeted therapy of patients with uveal melanoma. Mol Cancer Ther; 12(5); 768–76. ©2013 AACR. Mol Cancer Ther May 2013 12:768–76; Published OnlineFirst February 26, 2013; doi:10.1158/1535-7163.MCT-12-1020 24 aacrjournals.org
Mobile Access: Take the AACR Journals with you, wherever you go! Get access to AACR PUBLICATIONS on your smartphone and tablet. Search “AACR Publications” in the iTunes App Store to download the FREE app. The AACR online publications are available in a mobileoptimized format. The content presented on the mobile site is in a format designed specifically for the smaller screen size and functionality of a mobile device. This format, coupled with faster loading capabilities on low-bandwidth networks, provides easy access to journal articles. The mobile edition is compatible with most smartphones and mobile devices, including Blackberry, Droid and iPhone. iPhone and iPad users can access full-text AACR journal content through apps designed specifically for those devices. Search for “AACR Publications” in the iTunes App Store to download this FREE app. Learn more at AACRjournals.org
Page 1 and 2: THE BEST OF THE AACR JOURNALS Learn
Page 3 and 4: The Best of the AACR Journals The A
Page 5 and 6: Table of Contents Analysis of Tumor
Page 9 and 10: Cancer Cancer Discovery Discovery C
Page 11 and 12: Cancer Discovery Research Article A
Page 13 and 14: Cancer Epidemiology, Biomarkers & P
Page 15 and 16: In collaboration with the Cancer Im
Page 17 and 18: Cancer Immunology Research Research
Page 19 and 20: Cancer Prevention Research Research
Page 21 and 22: Cancer Research Cancer Research Geo
Page 23 and 24: Cancer Research Research Article Co
Page 25 and 26: Clinical Cancer Research Research A
Page 27 and 28: Molecular Cancer Research Molecular
Page 29 and 30: Molecular Cancer Research Research
Page 31: Molecular Cancer Therapeutics Resea

Best of AACR Journals

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?